Encompass Health (EHC) is back in focus after reporting first quarter results that topped analyst expectations on revenue and earnings, and after management raised full year 2026 guidance for the business.

The strong first quarter beat and raised 2026 guidance were followed by a 7.48% 1-day share price return, contributing to a 10.37% 30-day share price return. The 1-year total shareholder return remains a 7.24% decline and the 3-year total shareholder return is 75.96%, suggesting that recent momentum has strengthened after a weaker 12-month stretch.

If earnings-driven moves like this have your attention, it could be a good time to broaden your watchlist with 33 healthcare AI stocks

With Encompass Health trading at $107.48 and sitting at roughly a 31% discount to both its analyst price target and an intrinsic value estimate, you have to ask: is this a genuine opportunity, or is the market already baking in future growth?

Most Popular Narrative: 8.4% Overvalued

The narrative fair value of $99.17 sits below the last close of $107.48, which raises questions about whether the recent rebound has moved ahead of itself.

EHC has demonstrated consistent revenue growth and disciplined expansion through new hospital openings and occupancy improvements. The company benefits from demographic tailwinds, including an aging population and rising demand for post-acute rehabilitation services. Yet what may matter more long term is how effectively providers adapt to outcome-based healthcare frameworks.

The fair value view here leans heavily on steady revenue expansion, firm profit margins, and a future earnings multiple that assumes inpatient rehabilitation keeps its current relevance. Investors may be interested in which financial levers matter most in this recovery focused model and how they shape that $99.17 figure.

Result: Fair Value of $99.17 (OVERVALUED)

However, this narrative could be tested if outcome based reimbursement shifts unfavorably or if inpatient rehabilitation loses share to lower cost post acute options.

Another View: Earnings Multiple Points To Underpricing

The 8.4% overvalued narrative sits awkwardly next to how the market is actually pricing Encompass Health today. The current P/E of 18x is lower than the US Healthcare industry at 24.9x, close to peers at 18.2x, and below a fair ratio of 22.1x. This combination suggests the market could move higher if sentiment shifts.

In simple terms, the share price is being valued more cheaply than both the wider industry and the modelled fair ratio. This comes at a time when earnings have grown 19.8% over the past year and are forecast to grow 9.75% a year. It raises the question of whether this is a cushion against disappointment, or a sign that expectations are still too cautious for a business with high quality earnings and a 23.6% Return on Equity.

Next Steps

This mix of cautious and optimistic signals will not stay under the radar for long, so look through the numbers yourself, weigh both sides, and see how the 5 key rewards and 2 important warning signs fits your view.

Looking for more investment ideas?

If this Encompass Health move has you thinking about what else might be worth your attention, now is the moment to widen your search before the crowd catches up.

• Spot potential bargains early and size up companies that appear mispriced by starting with 52 high quality undervalued stocks.
• Prioritize resilience and sleep a little easier at night by reviewing companies in the 67 resilient stocks with low risk scores.
• Hunt for underfollowed names with solid fundamentals by checking the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.